Skip to main content
2024 AAPD Annual Meeting Main banner
Itinerary Planner Sponsored by Cheng Crowns
Information & Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Ticket Required
Ticket Required
Sold Out
Sold Out
Recorded Session
Recorded Session
Back
Rate ePoster
View ePoster

Pulp Therapy

396 - Radiographic Survival of 0.05% Oxymetazoline Used in Primary Pulp Therapy

Saturday, May 25, 2024
10:15 AM – 10:25 AM EST
Location: Exhibit Hall (back left corner of the hall, space 137)

    Presenting Author(s)

  • JJ

    Jingqi Jia, DDS, MS

    Pediatric Dental Resident
    University of Minnesota
    University of Minnesota
    Minneapolis, Minnesota, United States

    • Co-Author(s)

  • RJ

    Robert Jones, DDS, PhD

    University of Minnesota

    • Research Mentor(s)

  • Robert S. Jones, DDS, PhD

    Associate Professor
    University of Minnesota
    University of Minnesota
    Minneapolis, Minnesota, United States

    • Program Director(s)

  • Jeffrey Karp, D.M.D., M.S.

    Residency Program Director
    University of Minnesota, Minneapolis, MN
    School of Dentistry , University of Minnesota
    Minneapolis, Minnesota, United States

Abstract:  

Purpose: The purpose of this retrospective clinical study is to assess the radiographic survival of an oxymetazoline-based hemostatic agent used in primary pulp therapy.
 



Method: Pulpotomy treatment with CDT code D3220 performed at the University of Minnesota Pediatric Dental Clinic from 2018-2022 were reviewed. A total of 173 cases were included for data analysis. Restricted Mean Survival Time (RMST) for survival analysis to 30 months was used to compare the survival curves between ferric sulfate and nasal spray containing oxymetazoline (NS-OXY)

 

Result: Neither behavior (uncooperative vs compliant, P=.19, 95% CI [0.08-1.63]) nor the use of different hemostatic agents (NS-OXY vs ferric sulfate, P=.13, 95% CI [0.03-1.56]) was a significant predictor of radiographic failure. The estimated RMST up to 30 months was 28.1 months (SE: 0.48, 95% CI: [27.17-29.05]) for ferric sulfate and 29.3 months (SE: 0.64, 95% CI: [28.10-30.60]) for NS-OXY. MTA cases all survived and had a significant improvement of 2 months over IRM up to 30 months (P=.0001).

 



Conclusion: The survival time of teeth treated with ferric sulfate and with NS-OXY was comparable. This pilot study indicates that more investigation into the use of NS-OXY is warranted.

Identify Supporting Agency and Grant Number: None